Cambridge Nutritional Sciences
Plc
(the "Company" or "CNSL")
Directorate Change
CNSL (AIM:CNSL),
the specialist medical diagnostics company
focused on promoting a personalised and
functional approach to health and nutrition, is pleased to announce that it has appointed James Cooper to the Board as Chief Operating Officer
("COO") and Executive Director with immediate effect.
James graduated from the University
of Cambridge in 2014 and, prior to joining CNSL as Operations
Director in January this year, has spent the previous 10 years at
Chartwell Consulting Limited, a global operations consultancy firm,
working most recently on assignments in the medical and
pharmaceuticals sectors.
Carolyn Rand, Chair, said: "As a Board, we are committed to
strengthening both our operational performance and our organisation
to deliver profitable growth in an exciting market. We have created
a new Board level position of COO as part of this ongoing process
and are delighted to be promoting James into the role, who I am
certain will play a key part in our future
success".
Jag
Grewal, Chief Executive Officer, said: "In his short time
with us, James has already made a very significant contribution to
CNSL's manufacturing operations, and I am delighted that he has
agreed to step up to the role of COO where I look forward to
working closely with him to drive our business
forwards."
Contacts:
|
Cambridge Nutritional Sciences
Plc
|
www.cnsplc.com
|
|
Jag Grewal, Chief Executive
Officer
|
investors@cnsplc.com
|
|
|
|
|
Cavendish Capital Markets Limited
|
Tel: 020
7220 0500
|
|
Geoff Nash / Edward Whiley / George
Dollemore (Corporate Finance)
|
|
|
Nigel Birks / Harriet Ward
(ECM)
|
|
|
|
|
|
|
| |
About Cambridge Nutritional Sciences Plc
Cambridge Nutritional Sciences Plc
(AIM: CNSL) is a specialist medical diagnostics company focused on
industry-leading Health and Nutrition products.
The following disclosures are made
in accordance with Schedule 2(g) of the AIM Rules for
Companies:
James Samuel Cooper, aged 32, holds
265,480 ordinary shares of 4 pence each in the capital of the
Company representing 0.11 per cent. of the Company's issued share
capital. James holds no options in the Company. James has no
previous directorships or partnerships.
Save for the disclosures above,
there are no further disclosures to be made in accordance with Rule
17 and Schedule 2(g) of the AIM Rules.